Registered number
15360038
AFSHA PHARMS LTD
Filleted Accounts
31 March 2025
AFSHA PHARMS LTD
Registered number: 15360038
Balance Sheet
as at 31 March 2025
Notes 2025
£
Fixed assets
Tangible assets 3 900
Current assets
Debtors 4 4,915
Cash at bank and in hand 13,281
18,196
Creditors: amounts falling due within one year 5 (6,038)
Net current assets 12,158
Total assets less current liabilities 13,058
Creditors: amounts falling due after more than one year 6 (5,122)
Net assets 7,936
Capital and reserves
Called up share capital 100
Profit and loss account 7,836
Shareholders' funds 7,936
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
AFSHA ISHRAQ
Director
Approved by the board on 9 April 2025
AFSHA PHARMS LTD
Notes to the Accounts
for the year ended 31 March 2025
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 10 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2 Employees 2025
Number
Average number of persons employed by the company 1
3 Tangible fixed assets
Plant and machinery etc
£
Cost
Additions 1,000
At 31 March 2025 1,000
Depreciation
Charge for the year 100
At 31 March 2025 100
Net book value
At 31 March 2025 900
4 Debtors 2025
£
Trade debtors 4,915
5 Creditors: amounts falling due within one year 2025
£
Taxation and social security costs 5,486
Other creditors 552
6,038
6 Creditors: amounts falling due after one year 2025
£
Directors Loan 5,122
7 Controlling party
The company is under the full control of the sole director, by virtue of them owning the fully issued share capital.
8 Other information
AFSHA PHARMS LTD is a private company limited by shares and incorporated in England. Its registered office is:
41 GLOUCESTER ST. NORTH
OLDHAM
OL9 7RF
AFSHA PHARMS LTD 15360038 false 2024-04-01 2025-03-31 2025-03-31 VT Final Accounts July 2024 AFSHA ISHRAQ No description of principal activity 15360038 2024-04-01 2025-03-31 15360038 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 15360038 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 15360038 bus:Director40 2024-04-01 2025-03-31 15360038 1 2024-04-01 2025-03-31 15360038 2 2024-04-01 2025-03-31 15360038 countries:England 2024-04-01 2025-03-31 15360038 bus:FRS102 2024-04-01 2025-03-31 15360038 bus:FilletedAccounts 2024-04-01 2025-03-31 15360038 2025-03-31 15360038 core:WithinOneYear 2025-03-31 15360038 core:AfterOneYear 2025-03-31 15360038 core:ShareCapital 2025-03-31 15360038 core:RetainedEarningsAccumulatedLosses 2025-03-31 15360038 2024-03-31 iso4217:GBP xbrli:pure